<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111037</article-id><article-id pub-id-type="publisher-id">ACM-39996</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_97628760.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  慢性心力衰竭患者血清成纤维生长因子21水平变化及临床意义
  Changes and Clinical Significance of Serum Fibroblast Growth Factor 21 in Patients with Chronic Heart Failure
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>文丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>夏</surname><given-names>芳芳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>戴</surname><given-names>红艳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛市市立医院保健心内科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>潍坊医学院临床医学院，山东 潍坊</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>253</fpage><lpage>259</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨慢性心力衰竭(CHF)患者血清成纤维生长因子21 (FGF21)水平变化情况及临床意义。方法：选取2019年5月~2020年1月我院收治的72例慢性心力衰竭患者作为病例组，并进行NYHA心功能分级，其中心功能II级、心功能III级、心功能IV级患者分别为20例、22例、30例，选取同期体检的54例健康者作为对照组。收集各组患者临床基线资料，采取酶联免疫吸附试验法(ELISA)测定血清FGF21水平，并通过心脏超声测定左室射血分数(LVEF)。结果：血清FGF21水平在CHF组[(330.07 &#177; 91.98) pg/ml]明显高于对照组[(195.64 &#177; 27.08) pg/ml]，差异有统计学意义(P &lt; 0.05)；CHF组不同NYHA心功能分级患者之间血清FGF21水平差异有统计学意义(P &lt; 0.05)，即：心功能IV级[(399.24 &#177; 75.94) pg/ml] &gt; 心功能III级[(314.93 &#177; 61.96) pg/ml] &gt; 心功能II级[(242.96 &#177; 52.56) pg/ml]。Pearson相关分析显示：CHF组患者血清FGF21水平与NT-proBNP呈正相关(r = 0.534, P &lt; 0.01)，与LVEF呈负相关(r = −0.723, P &lt; 0.01)。ROC曲线分析示：血清FGF21用于诊断CHF时曲线下面积为0.902，此时FGF21的截断值为251.52 pg/ml，对应的灵敏度和特异度分别为80.6%、92.1%。结论：CHF患者血清FGF21水平显著升高，且升高程度与慢性心力衰竭严重程度呈正相关，有可能成为诊断慢性心力衰竭的新型生物学标志物。
    Objective: To investigate the changes and clinical significance of serum fibroblast growth factor 21 (FGF21) in patients with chronic heart failure (CHF). Methods: 72 patients with chronic heart failure treated in our hospital from May 2019 to January 2020 were selected as the case group, and NYHA cardiac function classification was performed. There were 20, 22 and 30 patients with cardiac function grade II, III and IV respectively, and 54 healthy subjects who underwent physical examination in the same period were selected as the control group. The clinical baseline data of patients in each group were collected, the serum FGF21 level was measured by enzyme-linked immunosorbent assay (ELISA), and the left ventricular ejection fraction (LVEF) was measured by cardiac ultrasound. Results: The serum FGF21 level in the CHF group [(330.07 &#177; 91.98) pg/ml] was significantly higher than that in the control group [(195.64 &#177; 27.08) pg/ml]. There were significant differences in serum FGF21 levels among patients with different NYHA cardiac function grades in the CHF group, that is, cardiac function grade IV [(399.24 &#177; 75.94) pg/ml] &gt; cardiac function grade III [(314.93 &#177; 61.96) pg/ml] &gt; cardiac function grade II [(242.96 &#177; 52.56) pg/ml]. Pearson correlation analysis showed that the level of serum FGF21 in the CHF group was positively correlated with NT-proBNP (r = 0.534, P &lt; 0.01), and negatively correlated with LVEF (r = 0.723, P &lt; 0.01). ROC curve analysis showed that when serum FGF21 was used to diagnose CHF, the area under the curve was 0.902, and the cutoff value of FGF21 was 251.52 pg/ml, and the corresponding sensitivity and specificity were 80.6% and 92.1%, respectively. Conclusion: The level of serum FGF21 in patients with CHF is significantly increased, and the degree of increase is positively correlated with the severity of chronic heart failure, which may become a new biological marker for the diagnosis of chronic heart failure. 
  
 
</p></abstract><kwd-group><kwd>成纤维生长因子21，慢性心力衰竭，心功能，标志物, Fibroblast Growth Factor 21</kwd><kwd> Chronic Heart Failure</kwd><kwd> Cardiac Function</kwd><kwd> Marker</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨慢性心力衰竭(CHF)患者血清成纤维生长因子21 (FGF21)水平变化情况及临床意义。方法：选取2019年5月~2020年1月我院收治的72例慢性心力衰竭患者作为病例组，并进行NYHA心功能分级，其中心功能II级、心功能III级、心功能IV级患者分别为20例、22例、30例，选取同期体检的54例健康者作为对照组。收集各组患者临床基线资料，采取酶联免疫吸附试验法(ELISA)测定血清FGF21水平，并通过心脏超声测定左室射血分数(LVEF)。结果：血清FGF21水平在CHF组[(330.07 &#177; 91.98) pg/ml]明显高于对照组[(195.64 &#177; 27.08) pg/ml]，差异有统计学意义(P &lt; 0.05)；CHF组不同NYHA心功能分级患者之间血清FGF21水平差异有统计学意义(P &lt; 0.05)，即：心功能IV级[(399.24 &#177; 75.94) pg/ml] &gt; 心功能III级[(314.93 &#177; 61.96) pg/ml] &gt; 心功能II级[(242.96 &#177; 52.56) pg/ml]。Pearson相关分析显示：CHF组患者血清FGF21水平与NT-proBNP呈正相关(r = 0.534, P &lt; 0.01)，与LVEF呈负相关(r = −0.723, P &lt; 0.01)。ROC曲线分析示：血清FGF21用于诊断CHF时曲线下面积为0.902，此时FGF21的截断值为251.52 pg/ml，对应的灵敏度和特异度分别为80.6%、92.1%。结论：CHF患者血清FGF21水平显著升高，且升高程度与慢性心力衰竭严重程度呈正相关，有可能成为诊断慢性心力衰竭的新型生物学标志物。</p></sec><sec id="s2"><title>关键词</title><p>成纤维生长因子21，慢性心力衰竭，心功能，标志物</p></sec><sec id="s3"><title>Changes and Clinical Significance of Serum Fibroblast Growth Factor 21 in Patients with Chronic Heart Failure<sup> </sup></title><p>Wenli Ma<sup>1</sup>, Fangfang Xia<sup>2</sup>, Hongyan Dai<sup>2*</sup></p><p><sup>1</sup>School of Clinical Medicine, Weifang Medical University, Weifang Shandong</p><p><sup>2</sup>Department of Healthcare Cardiology, Qingdao Municipal Hospital, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/37-1571876x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/37-1571876x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the changes and clinical significance of serum fibroblast growth factor 21 (FGF21) in patients with chronic heart failure (CHF). Methods: 72 patients with chronic heart failure treated in our hospital from May 2019 to January 2020 were selected as the case group, and NYHA cardiac function classification was performed. There were 20, 22 and 30 patients with cardiac function grade II, III and IV respectively, and 54 healthy subjects who underwent physical examination in the same period were selected as the control group. The clinical baseline data of patients in each group were collected, the serum FGF21 level was measured by enzyme-linked immunosorbent assay (ELISA), and the left ventricular ejection fraction (LVEF) was measured by cardiac ultrasound. Results: The serum FGF21 level in the CHF group [(330.07 &#177; 91.98) pg/ml] was significantly higher than that in the control group [(195.64 &#177; 27.08) pg/ml]. There were significant differences in serum FGF21 levels among patients with different NYHA cardiac function grades in the CHF group, that is, cardiac function grade IV [(399.24 &#177; 75.94) pg/ml] &gt; cardiac function grade III [(314.93 &#177; 61.96) pg/ml] &gt; cardiac function grade II [(242.96 &#177; 52.56) pg/ml]. Pearson correlation analysis showed that the level of serum FGF21 in the CHF group was positively correlated with NT-proBNP (r = 0.534, P &lt; 0.01), and negatively correlated with LVEF (r = 0.723, P &lt; 0.01). ROC curve analysis showed that when serum FGF21 was used to diagnose CHF, the area under the curve was 0.902, and the cutoff value of FGF21 was 251.52 pg/ml, and the corresponding sensitivity and specificity were 80.6% and 92.1%, respectively. Conclusion: The level of serum FGF21 in patients with CHF is significantly increased, and the degree of increase is positively correlated with the severity of chronic heart failure, which may become a new biological marker for the diagnosis of chronic heart failure.</p><p>Keywords:Fibroblast Growth Factor 21, Chronic Heart Failure, Cardiac Function, Marker</p><disp-formula id="hanspub.39996-formula26"><graphic xlink:href="//html.hanspub.org/file/37-1571876x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/37-1571876x8_hanspub.png" /> <img src="//html.hanspub.org/file/37-1571876x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>成纤维生长因子21 (fibroblast growth factor 21, FGF21)是一种调节机体中脂肪、葡萄糖动态平衡及能量代谢的肽类激素，主要在肝脏、脂肪组织中表达 [<xref ref-type="bibr" rid="hanspub.39996-ref1">1</xref>]，并通过旁分泌、内分泌等方式发挥各种生理作用 [<xref ref-type="bibr" rid="hanspub.39996-ref2">2</xref>]。早期研究证实，FGF21最显著的功效在于降低机体血糖、甘油三酯水平，因此FGF21被认为是代谢性疾病诊断或预后的生物学标志物，如糖尿病、肥胖、非酒精性脂肪肝等 [<xref ref-type="bibr" rid="hanspub.39996-ref3">3</xref>]。近几年研究表明，FGF21在心脏、血管组织中也有表达，具有减轻氧化应激、抗炎、抗细胞凋亡等作用 [<xref ref-type="bibr" rid="hanspub.39996-ref4">4</xref>]，并参与高血压、冠状动脉粥样硬化性心脏病、心肌病等心血管疾病的病理生理过程。但是，关于FGF21在慢性心力衰竭(chronic heart failure, CHF)患者中的水平变化少有研究。本研究通过ELISA法测定CHF患者血清中FGF21水平，旨在探讨血清FGF21对CHF是否具有诊断价值。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选取青岛市市立医院心血管内科2019年5月~2020年1月收治的72例慢性心力衰竭患者作为病例组，其中男性41例，女性31例，平均年龄(73.31 &#177; 13.12)岁；选取同期体检的54例健康者作为对照组，其中男性26例，女性28例，平均年龄(70.83 &#177; 8.02)岁。CHF组患者根据2018年中国心力衰竭诊断和治疗指南 [<xref ref-type="bibr" rid="hanspub.39996-ref5">5</xref>] 进行NYHA心功能分级，其中心功能II级组20例、心功能III级组22例、心功能IV级组30例。1) 纳入标准：① CHF诊断符合2018年中国心力衰竭诊断和治疗指南；② 具有完备的临床基线资料；③ 本人及家属均同意，并签署知情同意书。2) 排除标准：① 无自主意识、不能应答患者；② 合并严重的肾脏、肝脏、内分泌系统、血液系统等疾病患者；③ 合并严重感染患者；④ 恶性肿瘤患者。以上所入选的研究对象均经本院医学伦理委员会同意批准。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>1) 一般临床资料：记录入选者性别、年龄、入院体重、身体质量指数(body mass index, BMI)、吸烟史、高血压史、冠心病史、糖尿病史。测量入院后次日清晨患者静息状态下收缩压、舒张压。</p><p>2) 血样收集并测定：采集病例组、对照组患者入院后次日清晨空腹外周静脉血2份，一份送至医院实验室，测定并记录甘油三酯(triglyceride, TG)、总胆固醇(total cholesterol, TC)、高密度脂蛋白(high density lipoprotein, HDL)、低密度脂蛋白(low density lipoprotein, LDL)、空腹血糖(fasting blood glucose, FBG)、氨基末端脑钠肽前体(nitrogen-terminal pro-brain natriuretic peptide, NT-proBNP)。另一份血样以3000 r/min的速度离心15 min，并分离出血清，保存于−80℃冰箱中。采用酶联免疫吸附试验法检测血清中FGF21水平。FGF21试剂盒(编号SEC918Hu)购自武汉云克隆公司。其原理具体为：将FGF21抗体包被于96孔微孔板中，制成固相载体，向微孔中分别加入标准品或标本，其中FGF21与连接于固相载体上的抗体结合，然后加入生物素化的FGF21抗体，在将未结合的生物素化抗体洗净后，加入HRP标记的亲和素，再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的FGF21浓度呈正相关。用酶标仪在450 nm波长下测定吸光度(OD值)，计算样品浓度。</p><p>3) 超声心动图：患者入院当天行超声心动图检查，记录左室射血分数(left ventricular ejection fraction, LVEF)。</p></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>使用SPSS22.0软件进行数据分析。据进行正态分布检验，符合正态分布的计量资料用均数 &#177; 标准差表对数示，非正态分布的的计量资料以中位数(四分位数)表示；两组间符合正态分布的数据比较采用独立样本t检验，非正态分布的计量资料采用Mann-Whitney U非参数检验；计数资料结果用例数(%)表示，各因素间相关性分析应用Spearman秩相关分析法；绘制ROC曲线，评估血清FGF21对CHF的诊断价值。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般资料的比较</title><p>CHF组与对照组相比，在年龄、性别、入院体重、BMI、收缩压、舒张压、LDL、HDL、TC、TG、FBG、吸烟史、高血压史、糖尿病史、冠心病史上差异无统计学意义(P &gt; 0.05)；CHF组患者LVEF水平低于对照组，血清NT-proBNP、FGF21水平明显高于对照组，差异有统计学意义(P &lt; 0.001)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general clinical data [ x &#175; &#177; s , n(%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >CHF组</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >70.83 &#177; 8.06</td><td align="center" valign="middle" >73.31 &#177; 13.12</td><td align="center" valign="middle" >0.195</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >26 (48.1)</td><td align="center" valign="middle" >41 (56.9)</td><td align="center" valign="middle" >0.327</td></tr><tr><td align="center" valign="middle" >入院体重(kg)</td><td align="center" valign="middle" >69.79 &#177; 9.04</td><td align="center" valign="middle" >70.54 &#177; 10.25</td><td align="center" valign="middle" >0.671</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >25.37 &#177; 2.01</td><td align="center" valign="middle" >25.13 &#177; 2.28</td><td align="center" valign="middle" >0.543</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >72.81 &#177; 9.37</td><td align="center" valign="middle" >73.54 &#177; 12.86</td><td align="center" valign="middle" >0.726</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >132.63 &#177; 14.58</td><td align="center" valign="middle" >127.39 &#177; 16.64</td><td align="center" valign="middle" >0.068</td></tr><tr><td align="center" valign="middle" >LDL (mmol/L)</td><td align="center" valign="middle" >2.44 &#177; 0.76</td><td align="center" valign="middle" >2.22 &#177; 0.72</td><td align="center" valign="middle" >0.095</td></tr><tr><td align="center" valign="middle" >HDL (mmol/L)</td><td align="center" valign="middle" >1.16 &#177; 0.25</td><td align="center" valign="middle" >1.09 &#177; 0.40</td><td align="center" valign="middle" >0.265</td></tr><tr><td align="center" valign="middle" >TC (mmol/L)</td><td align="center" valign="middle" >3.85 &#177; 0.57</td><td align="center" valign="middle" >4.05 &#177; 0.75</td><td align="center" valign="middle" >0.110</td></tr><tr><td align="center" valign="middle" >TG (mmol/L)</td><td align="center" valign="middle" >1.46 &#177; 1.04</td><td align="center" valign="middle" >1.15 &#177; 0.77</td><td align="center" valign="middle" >0.052</td></tr><tr><td align="center" valign="middle" >FBG (mmol/L)</td><td align="center" valign="middle" >5.84 &#177; 0.79</td><td align="center" valign="middle" >6.46 &#177; 2.21</td><td align="center" valign="middle" >0.051</td></tr><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" >14 (25.9)</td><td align="center" valign="middle" >19 (26.4)</td><td align="center" valign="middle" >0.953</td></tr><tr><td align="center" valign="middle" >高血压史</td><td align="center" valign="middle" >37 (68.5)</td><td align="center" valign="middle" >44 (61.1)</td><td align="center" valign="middle" >0.829</td></tr><tr><td align="center" valign="middle" >糖尿病史</td><td align="center" valign="middle" >19 (35.2)</td><td align="center" valign="middle" >30 (41.7)</td><td align="center" valign="middle" >0.285</td></tr><tr><td align="center" valign="middle" >冠心病史</td><td align="center" valign="middle" >40 (74.1)</td><td align="center" valign="middle" >51 (70.8)</td><td align="center" valign="middle" >0.796</td></tr><tr><td align="center" valign="middle" >LVEF (%)</td><td align="center" valign="middle" >59.06 &#177; 3.06</td><td align="center" valign="middle" >27.93 &#177; 4.97</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >NT-proBNP (pg/ml)</td><td align="center" valign="middle" >109.01 &#177; 124.75</td><td align="center" valign="middle" >4621.94 &#177; 2551.70</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >FGF21 (pg/ml)</td><td align="center" valign="middle" >195.64 &#177; 27.08</td><td align="center" valign="middle" >330.07 &#177; 91.98</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表1. 一般临床资料比较[ X &#175; &#177; S，例(%)]</p></sec><sec id="s7_2"><title>3.2. 不同NYHA心功能分级患者血清FGF21、NT-proBNP、LVEF的比较</title><p>CHF组患者血清FGF21、NT-proBNP水平随心功能分级增加而升高，而LVEF水平随心功能分级增加而降低，差异有统计学意义(P &lt; 0.01)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> CHF comparison of serum FGF21, NT-proBNP and LVEF of patients with different NYHA ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >FGF21 (pg/ml)</th><th align="center" valign="middle" >NT-proBNP (pg/ml)</th><th align="center" valign="middle" >LVEF (%)</th></tr></thead><tr><td align="center" valign="middle" >心功能II级</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >242.96 &#177; 52.56</td><td align="center" valign="middle" >2648.21 &#177; 748.76</td><td align="center" valign="middle" >33.00 &#177; 3.96</td></tr><tr><td align="center" valign="middle" >心功能III级</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >314.93 &#177; 61.96<sup>＃</sup></td><td align="center" valign="middle" >3910.99 &#177; 1211.27<sup>＃</sup></td><td align="center" valign="middle" >28.59 &#177; 3.45<sup>＃</sup></td></tr><tr><td align="center" valign="middle" >心功能IV级</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >399.24 &#177; 75.94<sup>＃</sup><sup>*</sup></td><td align="center" valign="middle" >6459.13 &#177; 2819.51<sup>＃</sup><sup>*</sup></td><td align="center" valign="middle" >24.07 &#177; 2.86<sup>＃</sup><sup>*</sup></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td></tr></tbody></table></table-wrap><p>表2. CHF不同NYHA患者血清FGF21、NT-proBNP、LVEF的比较( X &#175; &#177; S)</p><p>注：与心功能II级组相比较，<sup>＃</sup>P &lt; 0.01；与心功能III级组相比较，<sup>*</sup>P &lt; 0.01。</p></sec><sec id="s7_3"><title>3.3. CHF患者血清FGF21水平与其他临床指标间的相关性分析</title><p>CHF患者血清FGF21水平与NT-proBNP水平(r = 0.534, P &lt; 0.001)呈正相关，与LVEF水平(r = −0.723, P &lt; 0.001)呈负相关，与年龄、性别、入院体重、BMI、收缩压、舒张压、LDL、HDL、TC、TG等指标无显著相关性(P &gt; 0.05)，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Analysis of correlation between serum FGF21 level and other clinical indexes in patients with CH</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >r值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.048</td><td align="center" valign="middle" >0.687</td></tr><tr><td align="center" valign="middle" >体重</td><td align="center" valign="middle" >0.033</td><td align="center" valign="middle" >0.786</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >−0.075</td><td align="center" valign="middle" >0.532</td></tr><tr><td align="center" valign="middle" >收缩压</td><td align="center" valign="middle" >0.054</td><td align="center" valign="middle" >0.651</td></tr><tr><td align="center" valign="middle" >舒张压</td><td align="center" valign="middle" >−0.084</td><td align="center" valign="middle" >0.485</td></tr><tr><td align="center" valign="middle" >LDL</td><td align="center" valign="middle" >0.101</td><td align="center" valign="middle" >0.400</td></tr><tr><td align="center" valign="middle" >HDL</td><td align="center" valign="middle" >−0.083</td><td align="center" valign="middle" >0.487</td></tr><tr><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >0.098</td><td align="center" valign="middle" >0.413</td></tr><tr><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >−0.17</td><td align="center" valign="middle" >0.154</td></tr><tr><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >0.109</td><td align="center" valign="middle" >0.362</td></tr><tr><td align="center" valign="middle" >LVEF</td><td align="center" valign="middle" >−0.723</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >NT-proBNP</td><td align="center" valign="middle" >0.534</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表3. CHF患者血清FGF21水平与其他临床指标间的相关性分析</p></sec><sec id="s7_4"><title>3.4. 血清FGF21对CHF诊断的价值分析结果</title><p>血清FGF21诊断CHF的ROC曲线下面积(area under curve, AUC)为0.902 (95% CI: 0.825~0.907, P &lt; 0.01)，最佳截断值为251.52 pg/ml，对应的灵敏度和特异度分别为80.6%、92.1%，见图1。</p><p>图1. 血清FGF21诊断CHF的ROC曲线</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>CHF是由心脏结构或功能异常引起的心室充盈和(或)射血能力受损的临床综合征，以体循环和(或)肺循环淤血为临床表现，是各种心脏疾病发展的终末阶段，其预后差、死亡率高 [<xref ref-type="bibr" rid="hanspub.39996-ref6">6</xref>]。心力衰竭标志物的出现与应用有利于临床上心衰的诊断，如BNP、NT-proBNP等，随着研究的不断进展，越来越多心衰标志物被发现，对心衰的诊断及预后的评估具有极高的临床意义。Chou等 [<xref ref-type="bibr" rid="hanspub.39996-ref7">7</xref>] 在一项针对舒张性心力衰竭患者的研究中发现，血浆FGF21和NT-proBNP水平在舒张性心力衰竭患者中显著升高，研究首次指出血浆FGF21水平与心脏舒张功能障碍有关。随后Shen等 [<xref ref-type="bibr" rid="hanspub.39996-ref8">8</xref>] 研究发现，血清FGF21水平升高是左室收缩功能不全的独立危险因素，且高水平血清FGF21患者发生心力衰竭等心血管不良事件风险显著升高。本研究显示，CHF组患者中血清FGF21水平与对照组相比显著升高，且不同NYHA心功能分级患者中血清FGF21水平比较：心功能IV级组 &gt; 心功能III级组 &gt; 心功能II级组，提示血清FGF21水平与心功能分级呈正相关，表明血清FGF21在一定程度上可反映患者慢性心力衰竭的严重程度。</p><p>NT-proBNP是一种比BNP半衰期长、稳定性好的分子，在临床上通常与LVEF结合以评价心力衰竭患者心脏功能。在健康人体内，NT-proBNP含量较少，但当出现心肌缺血缺氧、心脏负荷过大时，左心室分泌NT-proBNP增多，起到扩张血管、利尿排钠、抑制交感神经等作用，且NT-proBNP升高程度与心衰的严重程度呈正相关，可作为心力衰竭诊断的指标之一 [<xref ref-type="bibr" rid="hanspub.39996-ref9">9</xref>]。本研究中，Spearman秩相关分析示：血清FGF21水平与NT-proBNP水平呈正相关，与LVEF呈负相关，进一步表明血清FGF21水平在一定程度上可评估CHF的严重程度。本研究还绘制了ROC曲线以分析FGF21在CHF中的诊断价值，结果分析示血清FGF21诊断CHF的AUC为0.902，提示血清FGF21对CHF有较高的诊断价值，对应的灵敏度和特异度分别为80.6%、92.1%，表明血清FGF21诊断CHF的灵敏度稍差，特异性较好，提示FGF21在诊断CHF时仍需与患者临床症状或其他指标相结合。</p><p>FGF21是FGF家族的第21个成员，最早由Nishimura等 [<xref ref-type="bibr" rid="hanspub.39996-ref10">10</xref>] 首先在小鼠肝脏组织中发现，近年来，FGF21在冠心病 [<xref ref-type="bibr" rid="hanspub.39996-ref11">11</xref>]、高血压 [<xref ref-type="bibr" rid="hanspub.39996-ref12">12</xref>]、房颤 [<xref ref-type="bibr" rid="hanspub.39996-ref13">13</xref>] 等心血管疾病中的研究较多，而FGF21与慢性心力衰竭之间的关系却少有研究。根据现有研究，血清FGF21水平在慢性心力衰竭患者中升高的机制可能有以下几点：1) FGF21可参与心脏中氧化应激反应。心脏中过量的活性氧物质(reactive oxygen species, ROS)可导致心脏收缩功能减低、心室重构加快，进一步可导致慢性心力衰竭 [<xref ref-type="bibr" rid="hanspub.39996-ref14">14</xref>]。Ruperez等 [<xref ref-type="bibr" rid="hanspub.39996-ref15">15</xref>] 证实，FGF21基因敲除的小鼠中，抗氧化基因如解偶联蛋白(uncoupling protein, UCP) 2、UCP3、表达减少，活性氧物质增多，氧化应激作用增强，引起小鼠心室重构、心脏功能受损。2) FGF21可参与心肌细胞能量代谢。研究发现，心肌细胞能量代谢紊乱常是导致慢性心力衰竭的重要原因之一 [<xref ref-type="bibr" rid="hanspub.39996-ref16">16</xref>]。FGF21可通过提高三磷酸腺苷(adenosine triphosphate, ATP)合成酶水平恢复受损心肌的能量供应；另外，FGF21还可通过促进糖酵解途径产能，减少慢性心力衰竭的发生 [<xref ref-type="bibr" rid="hanspub.39996-ref17">17</xref>]。3) FGF21可抑制心脏中炎症反应。实验证实，大量的炎性因子可介导心室重构，炎症反应与慢性心力衰竭的发生发展密切相关 [<xref ref-type="bibr" rid="hanspub.39996-ref18">18</xref>]。Planavila等 [<xref ref-type="bibr" rid="hanspub.39996-ref19">19</xref>] 发现，FGF21基因敲除的小鼠输注异丙肾上腺素后，单核细胞趋化蛋白(monocyte chemotactic protein, MCP)-1、白细胞介素(interleukin, IL)-6等炎性因子活性增强，心脏重量增加、左心室扩张、心脏功能减退，给予外源性FGF21治疗后，小鼠心脏炎症反应减轻，心脏功能明显改善。更多作用机制尚需进一步研究。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，血清FGF21水平在慢性心力衰竭患者中升高，且升高程度与慢性心力衰竭严重程度呈正相关，有可能成为诊断慢性心力衰竭的新型生物学标志物。然而，本实验纳入样本量少，仍需大规模的多中心临床研究进一步证实。</p></sec><sec id="s10"><title>基金项目</title><p>青岛市医疗卫生优秀学科带头人项目(青卫科教字[<xref ref-type="bibr" rid="hanspub.39996-ref2019">2019</xref>]9号)。</p></sec><sec id="s11"><title>文章引用</title><p>马文丽,夏芳芳,戴红艳. 慢性心力衰竭患者血清成纤维生长因子21水平变化及临床意义Changes and Clinical Significance of Serum Fibroblast Growth Factor 21 in Patients with Chronic Heart Failure[J]. 临床医学进展, 2021, 11(01): 253-259. https://doi.org/10.12677/ACM.2021.111037</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39996-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Tabari, F.S., Karimian, A., Parsian, H., et al. (2019) The Roles of FGF21 in Atherosclerosis Pathogenesis. Reviews in Endocrine and Metabolic Disorders, 20, 103-114. &lt;br&gt;https://doi.org/10.1007/s11154-019-09488-x</mixed-citation></ref><ref id="hanspub.39996-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lakhani, I., Gong, M., Wong, W.T., et al. (2018) Fibroblast Growth Factor 21 in Cardio-Metabolic Disorders: A Systematic Review and Meta-Analysis. Metabolism, 83, 11-17. &lt;br&gt;https://doi.org/10.1016/j.metabol.2018.01.017</mixed-citation></ref><ref id="hanspub.39996-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Luo, Y. and Lu, W.J.C. (2018) Serum Levels of FGF21 and Prediction of Cardiovascular Events. Cardiology, 319, 219-221. &lt;br&gt;https://doi.org/10.1159/000486709</mixed-citation></ref><ref id="hanspub.39996-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Shi, Y., Wang, S., Peng, H., et al. (2019) Fibroblast Growth Factor 21 Attenuates Vascular Calcification by Alleviating Endoplasmic Reticulum Stress Mediated Apoptosis in Rats. International Journal of Biological Sciences, 15, 138-147.  
&lt;br&gt;https://doi.org/10.7150/ijbs.28873</mixed-citation></ref><ref id="hanspub.39996-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志, 2018, 46(10): 760-789.</mixed-citation></ref><ref id="hanspub.39996-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bryce, Y.C., Perez-Johnston, R., Bryce, E.B., et al. (2019) Pathophysiology of Right Ventricular Failure in Acute Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension: A Pictorial Essay for the Interventional Radiologist. Insights Imaging, 10, 18. &lt;br&gt;https://doi.org/10.1186/s13244-019-0695-9</mixed-citation></ref><ref id="hanspub.39996-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chou, R.H., Huang, P.H., Hsu, C.Y., et al. (2016) Circulating Fibroblast Growth Factor 21 Is Associated with Diastolic Dysfunction in Heart Failure Patients with Preserved Ejection Fraction. Scientific Reports, 6, Article No. 33953.  
&lt;br&gt;https://doi.org/10.1038/srep33953</mixed-citation></ref><ref id="hanspub.39996-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Shen, Y., Zhang, X., Xu, Y., et al. (2017) Serum FGF21 Is Associated with Future Cardiovascular Events in Patients with Coronary Artery Disease. Cardiovascular Diabetology, 16, 106. &lt;br&gt;https://doi.org/10.1186/s12933-017-0588-5</mixed-citation></ref><ref id="hanspub.39996-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">杨鸿媚, 安广隶, 孙娜. NT-proBNP、LVEF在老年慢性充血性心力衰竭评估中的作用[J]. 解放军医药杂志, 2019, 31(2): 52-55.</mixed-citation></ref><ref id="hanspub.39996-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nishimura, T., Nakatake, Y., et al. (2000) Identification of a Novel FGF, FGF-21, Preferentially Expressed in the Liver. Biochimica et Biophysica Acta, 1492, 203-206. &lt;br&gt;https://doi.org/10.1016/S0167-4781(00)00067-1</mixed-citation></ref><ref id="hanspub.39996-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Maida, A., Zota, A., Vegiopoulos, A., et al. (2018) Dietary Protein Dilution Limits Dyslipidemia in Obesity through FGF21-Driven Fatty Acid Clearance. Journal of Nutritional Biochemistry, 57, 189-196.  
&lt;br&gt;https://doi.org/10.1016/j.jnutbio.2018.03.027</mixed-citation></ref><ref id="hanspub.39996-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">史雨晨, 柳景华. 成纤维细胞生长因子21与心血管疾病关系的研究进展[J]. 中国医药, 2018, 13(9): 1430-1433.</mixed-citation></ref><ref id="hanspub.39996-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wang, R., Yi, X., Li, X., et al. (2015) Fibroblast Growth Factor-21 Is Positively Associated with Atrial Fibrosis in Atrial Fibrillation Patients with Rheumatic Heart Disease. International Journal of Clinical and Experimental Pathology, 8, 14901-14908.</mixed-citation></ref><ref id="hanspub.39996-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Mancini, A., Vergani, E., Bruno, C., et al. (2018) Oxidative Stress as a Possible Mechanism Underlying Multi-Hormonal Deficiency in Chronic Heart Failure. European Review for Medical and Pharmacological Sciences, 22, 3936-3961.</mixed-citation></ref><ref id="hanspub.39996-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Rupérez, C., Lerin, C., Ferrer-Curriu, G., et al. (2018) Autophagic Control of Cardiac Steatosis through FGF21 in Obesity-Associated Cardiomyopathy. International Journal of Cardiology, 260, 163-170.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2018.02.109</mixed-citation></ref><ref id="hanspub.39996-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X.L., Liu, Z.R., Xue, Y.J., et al. (2017) Dual PPARα/γ Ligand TZD18 Improves Myocardial Metabolic Remodeling after Myocardial Infarction in Rats. European Review for Medical and Pharmacological Sciences, 21, 5765-5773.</mixed-citation></ref><ref id="hanspub.39996-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Cong, W.T., Ling, J., Tian, H.S., et al. (2013) Proteomic Study on the Protective Mechanism of Fibroblast Growth Factor 21 to Ischemia-Reperfusion Injury. Canadian Journal of Physiology and Pharmacology, 91, 973-984.  
&lt;br&gt;https://doi.org/10.1139/cjpp-2012-0441</mixed-citation></ref><ref id="hanspub.39996-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Li, J.Y., Wang, N., Khoso, M.H., et al. (2018) FGF-21 Elevated IL-10 Production to Correct LPS-Induced Inflammation. Inflammation, 41, 751-759. &lt;br&gt;https://doi.org/10.1007/s10753-018-0729-3</mixed-citation></ref><ref id="hanspub.39996-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Planavila, A., Redondo, I., Hondares, E., et al. (2013) Fibroblast Growth Factor 21 Protects against Cardiac Hypertrophy in Mice. Nature Communications, 4, 2019. &lt;br&gt;https://doi.org/10.1038/ncomms3019</mixed-citation></ref></ref-list></back></article>